Meseclazone has anti-inflammatory, analgesic, and antipyretic activity. Meseclazone shows inhibitory potency of secondary phase ADP aggregation.

Intravenous administration of Meseclazone and other nonsteroidal anti-inflammatory drugs induced a dose-dependent inhibition of bronchoconstriction. This causing the following order of descending potency: isoproterenol congruent to indomethacin greater than fenoprofen greater than tolmetin greater than aspirin greater than naproxen congruent to ibuprofen greater than phenylbutazone greater than diflunisal greater than Meseclazone greater than 5-CSA. Meseclazone inhibits collagen-induced aggregation 1 and 4 hr after oral administration[1][2].

29053-27-8

C11H10ClNO3

239.66

NSC297623;W2395;美西拉宗;Meseclazone

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years